Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across more than 165 countries and territories [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter issued by the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results released on February 27, 2025, Viatris disclosed that the negative impact from the Indore facility's inspection would lower 2025 revenue by approximately $500 million and earnings from operations by approximately $385 million [5]. - Following this announcement, Viatris's stock price fell about 15%, dropping from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

If you invested in Civitas you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/civitas-resources-inc. NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Resources, Inc. (NYSE: CIVI) and certain of the Company's senior executives for potential violations of the federal securities laws. Investors have until July 1, 2025, to ask the Court to be appointed ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UnitedHealth Group Incorporated (NYSE: UNH) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UnitedHealth you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/unitedhealth-group-incorporated. Investors have until July 7, 2025, to ask the ...

Investors have until June 10, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased BigBear.ai securities. The case is pending in the U.S. District Court for the Eastern District of Virginia and is captioned Priewe v. BigBear.ai Holdings, Inc., et al., No. 25-cv-00623. Why was BigBear.ai Sued for Securities Fraud? BigBear.ai is an AI-driven technology solutions company t ...

Core Viewpoint - A lawsuit has been filed against The Bancorp, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation of risks associated with its loan portfolio [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Delaware, captioned Linden v. The Bancorp, Inc., et al., No. 25-cv-00326, with investors having until May 16, 2025, to seek lead plaintiff status [2]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Bancorp stock [2]. Group 2: Company Overview - Bancorp is a financial holding company involved in institutional banking, commercial real estate bridge lending, small business lending, and commercial fleet leasing, with its REBL loans primarily collateralized by apartment buildings [3]. Group 3: Allegations of Misrepresentation - The complaint alleges that Bancorp misrepresented the significant risk of default or loss on its REBL loan portfolio and that its credit loss methodology was inadequate [4]. - It is claimed that Bancorp misrepresented the effectiveness of its internal controls over financial reporting, which contained at least one material weakness [4]. Group 4: Stock Performance and Impact - Following a report from Culper Research on March 21, 2024, which highlighted misrepresentation of risks, Bancorp's stock price fell over 10%, from $36.04 to $32.12 [5]. - On October 24, 2024, Bancorp reported a net income of $51.5 million, leading to a 14% decline in stock price from $54.96 to $47.01 due to increased credit losses [6]. - On March 4, 2025, Bancorp disclosed inappropriate filing of its Annual Report, causing a 4.4% drop in stock price from $53.59 to $51.25 [7].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elevance Health, Inc. common stock during the specified Class Period, indicating potential misrepresentation by the company regarding Medicaid cost trends and premium negotiations [1][5]. Group 1: Class Action Details - The class action is for investors who purchased Elevance Health common stock between April 18, 2024, and October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its financial guidance for 2024 [5]. - It is alleged that the company assured investors that rising Medicaid expenses were adequately reflected in its guidance, while in reality, the acuity and utilization of Medicaid members were increasing significantly [5]. - The lawsuit suggests that the members being removed from Medicaid were healthier than those who remained, which was not accounted for in Elevance's rate negotiations or financial forecasts [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

NEW YORK, May 14, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Bitfarms Ltd. (NASDAQ: BITF) between March 21, 2023 and December 9, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2025.So What: If you purchased Bitfarms securities during the Class Period you may b ...

Group 1 - Johnson Fistel, PLLP is investigating Autodesk, Inc. to determine if there have been violations of federal and/or state laws by its executive officers or associated parties [1][2] - The investigation focuses on Autodesk's corporate governance practices and whether they comply with established legal precedents regarding fiduciary duties [2] - Johnson Fistel is a nationally recognized law firm specializing in shareholder rights, representing both individual and institutional investors in securities class action lawsuits [3] Group 2 - In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, highlighting its effectiveness in advocating for investors [4] - The firm has recovered approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel, marking its eighth recognition as a top plaintiffs' securities law firm in the U.S. [4]

Core Viewpoint - A lawsuit has been filed against UnitedHealth Group Incorporated and certain senior executives for potential violations of federal securities laws, alleging a corporate strategy of improperly denying health coverage to increase profits [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Faller v. UnitedHealth Group Incorporated, et al., No. 25-cv-03799 [2]. - Investors have until July 7, 2025, to request to be appointed to lead the case [2]. Group 2: Allegations and Corporate Strategy - The complaint claims that UnitedHealth has engaged in a long-term strategy of denying health coverage, which has led to regulatory scrutiny and public backlash [3]. - The strategy reportedly contributed to the death of the CEO of UnitedHealthcare in December 2024, prompting the company to ease its denial of health insurance claims while maintaining previous financial guidance [3]. Group 3: Stock Performance and Financial Guidance - On April 17, 2025, UnitedHealth reduced its full-year 2025 financial guidance, citing heightened care activity in its Medicare Advantage business, leading to a stock price decline of over 22%, from $585.04 to $454.11 per share [4]. - Following the unexpected departure of CEO Andrew Witty on May 13, 2025, the stock price fell more than 10% during trading on the same day [5].

Core Viewpoint - EchoStar Corporation is under investigation for potential securities fraud and unlawful business practices, following a significant drop in its stock price due to regulatory scrutiny from the FCC regarding its compliance with federal requirements for building a nationwide 5G network [1][3]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of EchoStar investors, focusing on possible securities fraud or other unlawful business practices by the company and its officers [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]. Group 2: Regulatory Scrutiny and Market Reaction - The FCC has initiated an investigation into EchoStar's compliance with federal requirements for its Boost Mobile subsidiary, which aims to establish a competitive wireless operation [3]. - Following the news of the FCC's investigation, EchoStar's stock price fell by $4.01, representing a 16.58% decrease, closing at $20.18 per share on May 12, 2025 [3].